Mazza Marianna, Di Nicola Marco, Martinotti Giovanni, Taranto Colombo, Pozzi Gino, Conte Gianluigi, Janiri Luigi, Bria Pietro, Mazza Salvatore
Institute of Psychiatry, Bipolar Disorders Unit, Catholic University of Sacred Heart, Rome, Italy.
Expert Opin Pharmacother. 2007 Apr;8(5):649-56. doi: 10.1517/14656566.8.5.649.
Oxcarbazepine (OXC) is a keto-congener of carbamazepine, which has fewer side effects and drug interactions. However, the efficacy of OXC in treating bipolar disorder is not as well established as that of carbamazepine. This article is a systematic literature review of all studies regarding OXC and bipolar disorders, with particular attention to papers published in the last 6 years. Using the terms 'oxcarbazepine and bipolar disorder', 'oxcarbazepine and mania' or 'oxcarbazepine and bipolar depression', a computer-aided search of MEDLINE for the years 2000-2006 has been conducted. Since its introduction as an antiepileptic drug in early 2000, clinical research regarding the potential role of OXC in the treatment of bipolar disorder remains limited. There is a lack of double-blind, placebo-controlled studies. Studies recently published have small samples of patients, with insufficient follow-up periods and other methodological weaknesses. The efficacy of OXC in bipolar disorder has not been widely studied. Some authors recommend using OXC as monotherapy or as add-on therapy in refractory mania, although results are not conclusive. It is unknown whether OXC has efficacy in the maintenance treatment of bipolar disorder. OXC can be particularly useful as an add-on treatment in bipolar disorder patients for whom previous treatments have failed, or in patients who have difficulty tolerating adequate dosages of standard approved treatments.
奥卡西平（OXC）是卡马西平的酮类似物，其副作用和药物相互作用较少。然而，奥卡西平治疗双相情感障碍的疗效不如卡马西平明确。本文是对所有关于奥卡西平和双相情感障碍研究的系统文献综述，特别关注过去6年发表的论文。使用“奥卡西平和双相情感障碍”、“奥卡西平和躁狂症”或“奥卡西平和双相抑郁”等术语，对2000 - 2006年的MEDLINE进行了计算机辅助检索。自2000年初作为抗癫痫药物引入以来，关于奥卡西平在双相情感障碍治疗中潜在作用的临床研究仍然有限。缺乏双盲、安慰剂对照研究。最近发表的研究患者样本量小，随访期不足且存在其他方法学缺陷。奥卡西平在双相情感障碍中的疗效尚未得到广泛研究。一些作者建议在难治性躁狂症中使用奥卡西平作为单一疗法或附加疗法，尽管结果尚无定论。奥卡西平在双相情感障碍维持治疗中是否有效尚不清楚。奥卡西平作为附加治疗对先前治疗失败的双相情感障碍患者或难以耐受标准批准治疗足够剂量的患者可能特别有用。
